NCCN Guidelines® Insights - Pancreatic Adenocarcinoma, Version 2.2014
The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas of the exocrine pancreas and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize major discussion points of the 2014 NCCN Pancreatic Adenocarcinoma panel meeting. The panel discussion focused mainly on the management of borderline resectable and locally advanced disease. In particular, the panel discussed the definition of borderline resectable disease, role of neoadjuvant therapy in borderline disease, role of chemoradiation in locally advanced disease, and potential role of newer, more active chemotherapy regimens in both settings.
This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to NCCN Guidelines for Pancreatic Adenocarcinoma
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Pancreatic Adenocarcinoma
- 1.00 Participation
- 1.00 Nurse
- 1.00 Pharmacist
- 1.00 Physician